glp 1 for weight loss covered by insurance Perspectives from employers on the costs and issues associated with covering GLP-1 agonists The GLP-1 Access Gap: Mapping

BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy

Preclinical studies have evaluated the therapeutic potential of GLP-1 based polypharmacology for the treatment of obesity and diabetes

2024;6:ojae069

Ozempic contains semaglutide and is approved for type 2 diabetes, while Wegovy contains semaglutide and is approved for chronic weight management

Current evidence strongly supports the safety of GLP-1 medications regarding thyroid cancer risk when used appropriately

and intestinal symptoms can include constipation, diarrhoea and faecal incontinence